To determine eligibility to therapy targeting ALK, ROS1, RET, or MET alterations [10–13], NSCLC treatment guidelines recommend testing for ALK, ROS1, RET fusions and MET exon 14 skipping [14, 15]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.